Leucine Zipper CAR Modules for High-Titer T-Cell Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genetic engineering strategies face challenges in stably integrating large CAR constructs into T cells for effective cancer treatment due to low viral titers and transduction efficiency, leading to inferior gene expression and potential toxicity.
Innovation Solution
A system comprising a membrane-bound polypeptide with a transmembrane domain, intracellular domain, and extracellular domain with dimerization domains, and a soluble polypeptide with a dimerization domain and antigen binding domain, utilizing leucine zipper domains to facilitate dimerization only when expressed from the same cell, along with optional chimeric antigen receptors and cytokines/chemokines for enhanced immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If large CAR constructs are integrated into T cells using viral vectors, then cancer targeting capability is improved, but transduction efficiency and gene expression levels deteriorate due to viral packaging limits
Solution Approach 1:
The patent divides the large CAR construct into multiple smaller modular units that can be individually packaged in viral vectors. Each module contains specific functional domains (extracellular antigen-binding domain, transmembrane domain, intracellular signaling domain) and can be independently transduced into T cells, then assembled through protein-protein interactions to form the complete CAR structure. This segmentation allows each viral vector to stay within packaging limits while achieving the functional equivalent of a large CAR construct.
Solution Approach 2:
The patent introduces intermediary proteins or domains that facilitate the assembly of segmented CAR modules after transduction. These intermediaries act as connectors or scaffolds that bring together the separately transduced molecular components, enabling the formation of functional multi-antigen targeting CAR structures without requiring simultaneous packaging of all components in a single viral vector.
2Reliability
If multiple tumor antigens are targeted to ensure potent cancer eradication, then cancer eradication efficacy is improved, but CAR construct size increases leading to lower viral titer
Solution Approach 1:
The patent segments the multi-antigen targeting CAR into separate modular units, each targeting a different tumor antigen. These modular CAR units can be distributed across multiple viral vectors, with each vector containing a manageable size construct. This allows the system to target multiple antigens (improving cancer eradication efficacy) while keeping individual viral constructs within packaging limits (maintaining viral titer).
Solution Approach 2:
The patent designs universal modular CAR components that can be combined in various configurations to target different antigen combinations. The standardized interface and structure allow the same basic module to target multiple different antigens by simply changing the extracellular binding domain, enabling flexible multi-antigen targeting without proportionally increasing overall construct complexity or size.
3Adaptability or versatility
If large CAR constructs are integrated into T cells, then multi-antigen targeting capability is improved, but copy number integration per cell deteriorates leading to inferior gene construct expression
Solution Approach 1:
The patent divides the multi-antigen CAR construct into separate transducible modules, allowing each module to be integrated into the T cell genome independently. This results in multiple integration events (higher copy number) rather than a single integration of a large construct, thereby improving both the quantity and quality of gene construct expression while maintaining multi-antigen targeting capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances immune activity and targeted cancer eradication with minimal toxicity by stabilizing large CAR constructs in T cells, improving transduction efficiency and gene expression, and activating antigen presenting cells.
Implementation Method 1
each of the first dimerization domain and the second dimerization domain comprises a leucine zipper domain
Data Source
AI summary
The presently disclosed subject matter provides compositions and systems for cell-based immunotherapy. In certain non-limiting embodiments, the system comprises a membrane-bound polypeptide and at least one soluble polypeptide that is capable of dimerizing with the membrane-bound polypeptide.